| Ident. | Authors (with country if any) | Title |
|---|
| 000429 (2014) |
Jay S. Schneider [États-Unis] ; Mark E. Ault ; David W. Anderson | Retinal pathology detected by optical coherence tomography in an animal model of Parkinson's disease. |
| 000628 (2014) |
Wai Kin D. Ko [France] ; Elsa Pioli ; Qin Li ; Steve Mcguire ; Audrey Dufour ; Todd B. Sherer ; Erwan Bezard ; Maurizio F. Facheris | Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. |
| 000767 (2013) |
Erwan Bezard [France] ; Elisabetta Tronci ; Elsa Y. Pioli ; Qin Li ; Gregory Porras ; Anders Björklund ; Manolo Carta | Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. |
| 000938 (2013) |
Jay S. Schneider [États-Unis] ; Elsa Y. Pioli ; Yang Jianzhong ; Qin Li ; Erwan Bezard | Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model. |
| 001309 (2011) |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease |
| 001944 (2010) |
Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates |
| 001D22 (2010) |
Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease |
| 001E39 (2010) |
Pershia Samadi [Canada] ; Marc Morissette [Canada] ; Daniel Lévesque [Canada] ; Thérèse Di Paolo [Canada] | BDNF levels are not related with levodopa‐induced dyskinesias in MPTP monkeys |
| 002182 (2009) |
Glenda Halliday [Australie] ; Maria Trinidad Herrero [Espagne] ; Karen Murphy [Australie] ; Heather Mccann [Australie] ; Francisco Ros-Bernal [Espagne] ; Carlos Barcia [Espagne] ; Hideo Mori [Japon] ; Francisco J. Blesa [Espagne] ; José A. Obeso [Espagne] | No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism |
| 002789 (2008) |
Jose L. Lanciego [Espagne] ; Maria C. Rodríguez-Oroz [Espagne] ; Francisco J. Blesa [Espagne] ; Lydia Alvarez-Erviti [Espagne] ; Jorge Guridi [Espagne] ; Pedro Barroso-Chinea [Espagne] ; Yoland Smith [États-Unis] ; Jose A. Obeso [Espagne] | Lesion of the centromedian thalamic nucleus in MPTP‐treated monkeys |
| 003245 (2006) |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa‐induced dyskinesias by a selective NR1A/2B N‐methyl‐D‐aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin |
| 003886 (2005) |
Pierre-Olivier Fernagut [États-Unis] ; Imad Ghorayeb [France] ; Elsa Diguet [France] ; François Tison [France] | In vivo models of multiple system atrophy |
| 003943 (2005) |
Pershia Samadi [Canada] ; Laurent Grégoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [États-Unis] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Paul J. Bédard [Canada] | Effect of kynurenine 3‐hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys |
| 004092 (2003) |
Jay S. Schneider [États-Unis] ; Timothy V. Wade [États-Unis] | Experimental parkinsonism is associated with increased pallidal GAD gene expression and is reversed by site‐directed antisense gene therapy |
| 004155 (2003) |
Nancy Bélanger [Canada] ; Laurent Grégoire [Canada] ; Abdallah Hadj Tahar [Canada] ; Paul J. Bédard [Canada] | Chronic treatment with small doses of cabergoline prevents dopa‐induced dyskinesias in parkinsonian monkeys |
| 004931 (2000) |
Imad Ghorayeb [France] ; Pierre O. Fernagut [France] ; Incarnation Aubert [France] ; Erwan Bezard [France] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] ; François Tison [France] | Toward a primate model of l‐dopa‐unresponsive parkinsonism mimicking striatonigral degeneration |
| 005017 (1998) |
Jay S. Schneider [États-Unis] ; Anne Pope-Coleman [États-Unis] ; Maria Van Velson [États-Unis] ; Frederique Menzaghi [États-Unis] ; G. Kenneth Lloyd [États-Unis] | Effects of SIB‐1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys |
| 005079 (1998) |
Pierre J. Blanchet [États-Unis] ; Spyridon Konitsiotis [États-Unis] ; Thomas N. Chase [États-Unis] | Amantadine reduces levodopa‐induced dyskinesias in parkinsonian monkeys |
| 005238 (1997) |
Lise Rioux [États-Unis] ; Paul A. Frohna [États-Unis] ; Joyce [États-Unis] ; Jay S. Schneider [États-Unis] | The effects of chronic levodopa treatment on pre‐ and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys |
| 005665 (1996) |
P. J. Blanchet [Canada] ; R. Grondin [Canada] ; Bédard [Canada] | Dyskinesia and wearing‐off following dopamine D1 agonist treatment in drug‐naive 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned primates |
| 005D97 (1993) |
Baltazar Gomez-Mancilla [Canada, Suisse] ; René Boucher [Canada, Suisse] ; Céline Gagnon [Canada, Suisse] ; Thérèse Di Paolo [Canada, Suisse] ; Rudolf Markstein [Canada, Suisse] ; Bédard [Canada, Suisse] | Effect of adding the D1 agonist CY 208–243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
